About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
C
The Improbable History of CAR T-Cells
By
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
FEATURING
Carl June
By
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies
FEATURING
Carl June
561 views
August 10, 2023
0 Comments
Login to view comments.
Click here to Login
Featured Video
24:08
Indy Hematology Review
Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…
Feat.
A. Tefferi
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Related Content
AUTOPLAY
ON
17:52
Indy Hematology Review
2024 Updates on Emerging & Current Treatment of Multiple Myeloma
Feat.
K. Anderson
16:42
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "The Best of Myeloma - Highlights & Key T…
Feat.
H. Hashmi
13:07
Moffitt Cancer Center
R/R DLBCL: Are Bispecific Antibodies Superior to CAR-T?
Feat.
J. Chavez
07:11
GRACE
CAR T-Cell vs. Bispecific Therapies for Blood Cancers: How Oncologis…
Feat.
A. Goodman,
A. Jeong,
S. Rajeeve
19:08
Insights from 2023 ASH Annual Meeting
ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGU…
Feat.
R. Banerjee
24:23
MyCancerHaven
Will CAR-Ts and Bispecifics Will Replace HSCT in Myeloma?
Feat.
R. Vij,
S. Al Hadidi
27:47
Indy Hematology Review
Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…
Feat.
S. Smith
45:56
Yale Cancer Center
Endocrine Adverse Events From Checkpoint Inhibitors
Feat.
K. Herold
24:35
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "The Best of Myeloma - Review of the Top 5 …
Feat.
H. Hashmi
05:35
Saurabh Chhabra
Bispecifics & CAR-Ts in MM: How to Choose and How to Sequence
20:19
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Highlights of Hematologic Malignancies - …
Feat.
A. Paulus
09:18
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Primary OS Analysis of the Phase 3 Random…
Feat.
J. Westin
10:04
Tara Graff
How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…
20:18
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Will Immune Therapy Replace Transplant in Hematologic Malignancies?
Feat.
R. Gale
35:27
Louisville Hematology Highlights
Updates on Management of DLBCL
Feat.
J. Leonard
12:38
SOHO 2022 Tenth Annual Meeting
SOHO 2022 DEBATE: Bispecific Antibodies vs. CAR-T for R/R MM - Defen…
Feat.
S. Usmani
26:46
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent F…
14:09
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Summary: "Multiple Myeloma Highlights and Clinical P…
Feat.
H. Hashmi
03:42
Moffitt Cancer Center
Multiple Myeloma: What You Need to Know About New FDA Approvals of C…
Feat.
D. Hansen
08:23
Total Health
R/R DLBCL Case Discussion: 81 y/o Male Needing 3rd Line Treatment
Feat.
J. Chandler,
B. Randolph,
M. Onciu